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Informing participants of allocation to placebo at trial
closure: postal survey
Zelda Di Blasi, Ted J Kaptchuk, John Weinman, Jos Kleijnen
Abstract
Objectives To assess whether and how investigators of
placebo controlled randomised trials inform
participants of their treatment allocation at trial
closure and to assess barriers to feedback.
Design Postal survey with a semistructured
questionnaire.
Participants All investigators who published a
placebo controlled randomised trial in 2000 in five
leading medical journals, and a random sample of
120 trials listed in the national research register
database.
Main outcome measures Number of investigators
who informed participants of their treatment
allocation at trial closure, methods for delivering the
information, and barriers to unmasking treatment.
Results 45% of investigators informed either all or
most participants of their treatment allocation, and
55% did not inform any participant or only informed
those who asked. The main reasons for not informing
participants were that the investigators never
considered this option (40%) or to avoid biasing
results at study follow up (24%).
Conclusion Further research is required to examine
sensitive ways to communicate treatment information
to trial participants.
Introduction
In 1948 the Medical Research Council introduced a
new experimental design to deal with therapeutic
uncertainties.1 The randomised controlled trial aimed
to ensure the absence of systematic differences
between treatment and control groups.2 Placebos—
surrogates for a control group receiving no
treatment—were gradually adopted to act as dummy
therapies to mimic the experimental treatment in
appearance but not in substance or chemical
structure.3 Placebos helped patient retention and
allowed the consequences of attention, expectation,
suggestion, and natural course to be separated from
the effects of the experimental treatment.
Initially investigators could recruit patients into
studies without needing to inform or ask them for their
consent to participate. Patients would often not be
aware that they might be taking placebos. Although
this approach may have kept the study purer, since at
least the early 1970s it has not been considered ethical
to withhold this information from patients before they
enter a trial.4
In March 2001 the Department of Health issued a
research governance framework to ensure that the
public could have confidence in, and benefit from,
quality research.5 The report states that once research
findings are established, principal investigators are
responsible for feeding back findings to participants or
their representatives promptly and appropriately.
Study results must be presented in a clear and compre›
hensible language for the general public and be easily
and freely accessible for users and care professionals.
Unmasking treatment allocation is not explicitly
discussed in the report. This is particularly relevant for
placebo controlled trials and especially for participants
who have responded to placebo, for whom treatment
disclosure may be a particularly sensitive issue. Placebo
responders are likely to have high expectations
towards the treatment and to attribute positive health
changes to this.6 7 When participants are informed that
their treatment consisted of a sham therapy, reactions
may be negative and the placebo response may be
disrupted.
We examined the extent to which recently
conducted trials conform to some of the recommenda›
tions of the research governance framework and
whether investigators of placebo controlled clinical
trials inform participants of their treatment arm. For
those who did inform participants, we assessed ways by
which this information was delivered to the placebo
group. We assessed barriers to information disclosure
and intention to inform participants in the future for
investigators who failed to inform trial participants. In
addition, we identified whether investigators informed
patients of study results.
Methods
We searched Medline to identify all placebo controlled
randomised clinical trials published in 2000 in five
leading medical journals: BMJ, Lancet, New England
Journal of Medicine, JAMA, and Annals of Internal
Medicine. Our search strategy was based on the fourth
report developed by the NHS Centre for Reviews and
Dissemination (see box).8
We also searched the national research register, a
register of ongoing and recently completed research
projects funded by, or of interest to, the UK’s NHS.9 We
were able to select a random sample of commercially
Department of
Health Sciences,
University of York,
York YO10 5DD
Zelda Di Blasi
PhD student
Osher Institute,
Harvard Medical
School, 401 Park
Drive, Boston,
MA 02215, USA
Ted Kaptchuk
assistant professor
Unit of Psychology,
Guy’s, King’s, and
St Thomas’s School
of Medicine,
London SE1 9RT
John Weinman
professor
NHS Centre for
Reviews and
Dissemination,
University of York,
York YO10 5DD
Jos Kleijnen
director
Correspondence to:
Z Di Blasi
zdb1@york.ac.uk
bmj.com 2002;325:1329
page 1 of 4BMJ VOLUME 325 7 DECEMBER 2002 bmj.com
 on 13 October 2004 bmj.comDownloaded from 
funded and non›commercially funded trials by using a
randomisation service based at the Health Services
Research Trials Support Unit at York university.
We sent the investigators a letter outlining our
aims, along with a short semistructured questionnaire.
To increase the response rate we sent out letters to
coauthors, and we sent reminders by email and then by
post.
Results
Overall, we excluded 27 of 119 potential trials because
they consisted of reviews, articles, letters, editorials, or
comments, leaving 92 placebo controlled randomised
trials. Of these, 25 were published in the Lancet, 24 in
the New England Journal of Medicine, 25 in JAMA, 5 in
the BMJ, and 13 in the Annals of Internal Medicine. By
using the term “placebo” in the national research reg›
ister, we identified 1973 completed trials (25 from the
Medical Research Council’s clinical trials’ directory).
We selected a random sample of 60 commercial and
60 non›commercial trials.
The response rate to the postal survey was 71% for
investigators of trials published in a medical journal
(65 of 92) and 62% for investigators of trials listed in
the national research register (74 of 120): total
response rate 66% (139 of 212). Overall, 23% (32 of
139) of these investigators (mostly of trials published in
the register) were unable to complete the question›
naire. In eight cases the trial was never conducted or
completed because of inadequate recruitment or lack
of funding. Five investigators had moved or retired. In
six cases the trial was not placebo controlled or the
questionnaire was not filled out because the study was
still ongoing. Two investigators believed that ethics
approval was needed for them to respond to our ques›
tionnaire. In seven cases the trial was either not blind,
was open, the investigator never participated in the
study, or patients were not entered in the trial. Four
investigators responded by forwarding our request to
relevant researchers, who never replied.
Overall, 107 investigators completed the question›
naire. Of these, 45% informed either all or most
participants of their treatment allocation, and 55% did
not inform any of their participants or informed only
those who asked (table 1).
Investigators of trials selected from the national
research register or commercially funded trials were
less likely to inform participants than investigators of
trials published in a leading journal or investigators of
trials not funded commercially.
Informing participants of treatment arm
Participants were generally informed in person (23 of
48, 48%), by post (12 of 48, 25%), or by telephone (4 of
48, 8%). In five cases more than one method was used
and in four cases investigators did not indicate how
they informed patients. Information about treatment
arm (in person or by telephone, n=32) was usually pro›
vided by a nurse (8, 25%), investigator (7, 22%), doctor
(5, 16%), or more than one professional (12, 38%). The
most common method for informing those ran›
domised to placebo was to simply tell them they were
in the placebo arm (54%) or to give them a common
definition of placebo effects (21%) (table 2).
A few investigators advised patients to follow up
this result with their doctor or gave them the
opportunity to ask questions or to discuss the option of
the active treatment. In one instance the investigator
did not know because “the actual message was given at
Medline search strategy
1. randomized controlled trial.pt.
2. randomized controlled trials.sh.
3. random allocation.sh.
4. double blind method.sh.
5. 1 or 2 or 3 or 4
To include only human studies
6. animal.sh.
7. human.sh.
8. 6 not (6 and 7)
9. 5 not 8
10. clinical trial.pt.
11. exp clinical trials/
12. (clin$ adj3 trial$).ti,ab
13. ((doubl$ or treb$ or tripl$) adj3 (blind$ or
mask$)).ti,ab.
14. random.ti,ab.
15. research design.sh.
16. 10 or 11 or 12 or 13 or 14 or 15
17. 16 not 8
18. comparative study.sh.
19. exp evaluation studies/
20. follow up studies.sh.
21. prospective studies.sh.
22. (control$ or prospectiv$ or volunteer$).ti,ab.
23. 18 or 19 or 20 or 21 or 22
24. 23 not 8
To include only placebo controlled trials
25. placebos.sh.
26. placebo$.ti,ab.
27. 25 or 26
28. 27 not 8
To include only top medical journals
29. bmj.jn
30. lancet.jn
31. new england journal of medicine.jn.
32. jama.jn
33. annals of internal medicine.jn
34. 28 and (9 or 17 or 24)
35. 34 and 35
36. limit 36 to yr=2000
Table 1 Unmasking of treatment allocation at study closure in placebo randomised controlled trials by source of publication and funding
Extent of informing participants No of trials
Source of publication Funding
Journal Register* Commercial Non›commercial
Commercial and
non›commercial
Information not
available
Informed all participants of treatment arm 40 26 14 13 20 5 2
Informed most participants of treatment arm 8 5 3 3 1 3 1
Did not inform any participants of treatment arm 53 27 26 25 15 8 5
Informed only participants who asked 6 3 3 6 0 0 0
*National research register.
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the discretion of the physician.” Some of the studies
used a crossover design and patients were simply told
they received both a placebo and an active treatment.
In one of these studies, patients were also told that if
they responded to placebo this probably resulted from
being in a trial and the positive effects of placebo. In
three cases, investigators explained the effect as a result
of spontaneous remission.
Reasons for not informing participants of
treatment arm
Overall, 53 investigators never informed any of their trial
participants about treatment allocation. The most com›
mon reasons were that they never considered this
option (21 investigators) or that they wanted to avoid
biasing results at study follow up (12 investigators), often
referring to studies that were still ongoing. Eight investi›
gators wanted to avoid extra costs and six wanted to
avoid both extra costs and administrative work. Six
investigators believed that participants did not need to
know; two explained that this was because of the
crossover nature of the study. In three cases participants
had died, and in single instances participants were not
informed to avoid interfering with the doctor›patient
relationship, because it was not relevant as it was “rather
old news,” to avoid distressing or upsetting patients, and
because it was not part of the methodology. Difficulty in
contacting patients was highlighted in two studies. In
one case patients came from an isolated community in
Kenya and it would have been difficult to trace them
after discharge. In another case the sample was based in
Sri Lanka, and participants lived more than 125 miles
(200 km) from the research facility. Many of the patients
were poor and did not have a postal address. Follow up
was considered pointless as previous attempts had a less
than 20% success rate.
Of the 53 investigators who did not inform partici›
pants, 40 (75%) would consider informing participants
of their treatment allocation in future studies.
Informing participants of study findings
Many (32 of 48; 67%) of the investigators who did
inform participants, also informed or would inform all
or most participants of the study results (table 3). In
trials where participants were not informed of their
treatment arm, five (9%) investigators informed partici›
pants of study results.
Although investigators were not directly asked
about reasons for not informing participants of study
findings, several did give an explanation. Reasons
included that the study was ongoing and results were
being analysed, the results were “too distant in time”
and “rather old news,” it was difficult to trace patients,
the results were unclear, none of the patients asked,
they were never asked by their sponsors, and most of
the uninformed participants were dead.
Discussion
Participants have less than a 50% chance of being
informed of their treatment allocation to placebo at
the end of a trial. The main reason for not unmasking
treatment allocation was that investigators never
considered this option or that they wanted to avoid
biasing results at follow up. A wide range of methods
were used to inform participants.
Patients need to be treated as participants rather
than subjects by increasing their involvement in the
trial process. Consumer involvement has been shown
to help priorities and to refine trial questions, improv›
ing the quality of patient information and making the
study more relevant to patients’ needs.10 11
During the informed consent procedure patients
are told that they may receive a placebo; this is usually
described as a harmless inactive substance or an inac›
tive dummy drug. We found that the most common
method of informing patients in the placebo arm was
to simply tell them that they were in this arm, without
giving possible explanations for this effect. Just as
knowing that patients have a 50% chance of being ran›
domised to a placebo has been shown to influence
health outcomes, it is possible that the placebo
response may be disrupted when the treatment is
unmasked to patients who have responded.12 Unmask›
ing the allocation of placebo may be a source of confu›
sion and disappointment to patients and may even
damage clinical relationships and have negative effects
on patients’ health, particularly in placebo surgery. For
this reason, feedback should be handled sensitively. A
recent trial evaluating the effects of antidepressants
found that when placebo responders were told that
they were receiving a placebo their mood deterio›
rated.13 Within a month 70% of the patients needed
antidepressants.14
In another study, 50 patients with depression who
responded to placebos over a 10 day single blind trial
were randomised in a double blind way to either
continue taking placebos for six weeks or to stop treat›
ment. Half in each group relapsed at six weeks.15
Therefore unmasking had no effect.
To avoid negative thoughts, misconceptions, or
mistrust in health professionals, patients must be well
informed. They could be told about the various debates
on the therapeutic effectiveness of placebos, but that
there is growing evidence for the healing effects of psy›
chological and social factors, such as positive expecta›
tions and good patient›doctor relationships.16 17
Study limitations
The lower response rate from investigators of trials
listed in the national research register is partly due to
Table 2 Method for informing participants about treatment allocation at study closure
Method for informing participants
No (%) of
participants
(n=48)
Told they were in placebo arm 26 (54)
Told they were in placebo arm and given common definition of placebo effects 10 (21)
Told they received active treatment and placebo in crossover study 4 (8)
Told placebo response derived from positive effects of being in trial 4 (8)
Told placebo response derived from positive effects of placebos 2 (4)
Told placebo response derived from positive effects of both being in trial and placebos 3 (6)
Told placebo response derived from natural or spontaneous remission 3 (6)
Data on how patients were informed not given 8 (17)
Table 3 Extent of informing participants of results at study closure. Values are
numbers (percentages) of participants
Extent of informing participants
Informed
(n=48)
Not informed
(n=53)
Informed only after
inquiry (n=6)
All or most informed 32 (67) 5 (9) —
Only those who asked informed 6 (13) 7 (13) 4 (67)
Nobody informed 6 (15) 37 (70) 2 (33)
Information not available 4 (8) 4 (8) —
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our inability to contact coauthors, as the name of only
one investigator is provided. At times up to six trials
were registered under the same investigator, who failed
to respond to repeated requests. Many of the trials in
the register were never completed, due to a lack of
funding or low recruitment rates, so although the
investigators replied they were unable to complete our
questionnaire.
Practical and research implications
A major gap is apparent in the literature examining
patient understanding of placebos and their effect.
Although there has been extensive discussion on the
ethics of giving placebos, we are unaware of any
systematic discussions on informing patients and full
disclosure at trial completion.18 If feeding back
treatment allocation and study results to the partici›
pants of placebo controlled trials is to become a stand›
ard part of trial protocols, research is required to
examine effective and sensitive ways to communicate
such information to participants who want to be
informed. Issues that need to be evaluated are at what
stage participants should be informed, whose role it is
to inform patients, and how best to feed back
information in large multicentre trials. Views about
treatment should be explored, assessing, for example,
the basis of preferences and examining when unmask›
ing may not be appropriate, such as in studies with
long term follow up.
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What is already known on this topic
Information is poor on the nature, extent, and
effect of informing participants of placebo
controlled randomised trials about their treatment
allocation at trial closure
Less than 50% of participants receiving placebo
are informed about their treatment allocation
What this study adds
No standard procedure is available for informing
patients of their treatment arm or of study results
at the end of a trial
Effective and sensitive ways of communicating
treatment allocation to participants are required,
as is information on the effects on placebo
responders
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